TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05138874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trending Feedback
Description: Clinicians randomized to Trending Feedback will receive monthly feedback on the provider dashboard page.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trending Feedback
Description: Clinicians randomized to Trending Feedback will receive monthly feedback on the provider dashboard page.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trending Feedback
Description: Clinicians randomized to Trending Feedback will receive monthly feedback on the provider dashboard page.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benchmark Peer Comparison Feedback
Description: Clinicians randomized to Benchmark Peer Comparison Feedback will receive monthly feedback on the provider dashboard page.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benchmark Peer Comparison Feedback
Description: Clinicians randomized to Benchmark Peer Comparison Feedback will receive monthly feedback on the provider dashboard page.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benchmark Peer Comparison Feedback
Description: Clinicians randomized to Benchmark Peer Comparison Feedback will receive monthly feedback on the provider dashboard page.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Private Commitment
Description: Clinicians assigned to the Private Commitment will be prompted in the provider dashboard to make a personal commitment to evidence-based use of antibiotics that will not be shared with their patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Private Commitment
Description: Clinicians assigned to the Private Commitment will be prompted in the provider dashboard to make a personal commitment to evidence-based use of antibiotics that will not be shared with their patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Private Commitment
Description: Clinicians assigned to the Private Commitment will be prompted in the provider dashboard to make a personal commitment to evidence-based use of antibiotics that will not be shared with their patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Commitment
Description: Clinicians assigned to Public Commitment will be prompted in the provider dashboard to make a commitment to evidence-based use of antibiotics that will be shared with their patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Commitment
Description: Clinicians assigned to Public Commitment will be prompted in the provider dashboard to make a commitment to evidence-based use of antibiotics that will be shared with their patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Commitment
Description: Clinicians assigned to Public Commitment will be prompted in the provider dashboard to make a commitment to evidence-based use of antibiotics that will be shared with their patients.
Study: NCT05133193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: three kinds of antibiotics
Description: All patients were educated carefully about the medical instructions, including the duration of treatment, possible side effect, the necessity of completing the full 14-day course.
Study: NCT05398393

Intervention type: DRUG
Group type: OTHER
Intervention: oral Tenofovir Amibufenamide 25mg each day
Description: patients in three groups respectively take one tablet of Tenofovir Amibufenamide(25mg) every day

Intervention type: DRUG
Group type: OTHER
Intervention: oral Tenofovir Amibufenamide 25mg each day
Description: patients in three groups respectively take one tablet of Tenofovir Amibufenamide(25mg) every day

Intervention type: DRUG
Group type: OTHER
Intervention: oral Tenofovir Amibufenamide 25mg each day
Description: patients in three groups respectively take one tablet of Tenofovir Amibufenamide(25mg) every day

Intervention type: DRUG
Group type: OTHER
Intervention: lipid lowering drugs (e.g. Atorvastatin and amlodipine.)
Description: lipid lowering drugs, , patients in group B1 continue take lipid lowering drugs
Study: NCT06010355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in focus groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Watch culturally appropriate video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Watch culturally appropriate video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test
Description: Complete test
Study: NCT05852678

Intervention type: OTHER
Intervention: cohort
Description: The Cantabria Cohort will recruit 40,000-50,000 residents aged 40-69 years at baseline
Study: NCT05603013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine Tartrate Oral

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: hypofractionated radiotherapy
Study: NCT05836519

Intervention type: OTHER
Intervention: Survey Navicular Drop test, International Physical Activity Questionnaire (IPAQ) Short Form, 6-minute walk test, Foot Function Index (AFI), SF-36 quality of life questionnaire, Modified borg scale
Description: Pulse oximetry will be used to measure the oxyhemoglobin value of the participants, and a sphygmomanometer will be used for blood pressure and heart rate measurements.

Intervention type: OTHER
Intervention: Survey Navicular Drop test, International Physical Activity Questionnaire (IPAQ) Short Form, 6-minute walk test, Foot Function Index (AFI), SF-36 quality of life questionnaire, Modified borg scale
Description: Pulse oximetry will be used to measure the oxyhemoglobin value of the participants, and a sphygmomanometer will be used for blood pressure and heart rate measurements.
Study: NCT05603013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitor
Description: PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 subcutaneous injection
Study: NCT04836806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine and Famotidine
Description: Participants will take 10 milligrams (mg) of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebos to match 10 mg of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
Study: NCT06498544

Intervention type: OTHER
Intervention: Exposure to 3600 m
Description: Participants will travel to and stay for 2 nights at an altitude of 3600 m.

Intervention type: OTHER
Intervention: Exposure to 3600 m
Description: Participants will travel to and stay for 2 nights at an altitude of 3600 m.
Study: NCT05429034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIST paradigm
Description: Patients are exposed to psychosocial stress = receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham paradigm
Description: Patients are not exposed to psychosocial stress = threat components from the program and/or the investigator are absent
Study: NCT05976295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jianpi Qushi Huatan Decoction
Description: The treatment group will receive the Jianpi Qushi Huatan Decoction (consisting of Radix astragali, Atractylodes Lancea, Dioscorea oppositifolia, Cyperus rotundus, Lindera aggregata, Aconitum gymnandrum and Ligusticum wallichii, among others). Subjects will take the medication from the first day of inclusion, dissolving and consuming one packet twice a day (morning and evening) for a total of three months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive a placebo treatment.
Study: NCT06563622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular Nerves Group Block
Description: USG-guided single-shot PENG in a dose of 0.5 ml/kg of 0.25% bupivacaine per side.
Study: NCT05877079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menthol
Description: Patients will wear hand and foot wraps with 8% w/w menthol lotion (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will wear hand and foot wraps with lotion without menthol (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
Study: NCT06420414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants engaged in a 15-minute HIIT session using the Facebook Oculus Quest 2 VR headset with the FitXR fitness game. The advanced level workout (High Speed) was chosen, where participants performed functional movements like squats, lunges, and trunk rotations while punching virtual targets. The VR environment provided a 10-second rest period between intervals and featured a virtual trainer's guidance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional HIIT
Description: Participants followed a non-VR 15-minute HIIT programme designed to replicate the exercises and patterns seen in the FitXR game. The traditional exercises included squats, lunges, and punches, matching the VR programme's intensity and interval structure. Participants watched a pre-recorded video on a laptop, which guided them through the workout. The 10-second rest periods were also maintained for consistency.
Study: NCT06241859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)
Description: Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to maintain a sedation depth between 80-90 value, which corresponds to light sedation definition.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)
Description: Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to monitor sedation depth.
Study: NCT05852808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular steroid injections
Description: The patient will be placed in prone position and the facet joints will be imaged by pa-radiation path with attention to radiation protection. 20 mg Kenacort + 1 ml Bupivacain (2.5 mg/ml) will be injected into the affected facet joints. The patient is monitored after the intervention for another 30 minutes before leaving the hospital. In order to track the pain level, the patient will be instructed to keep a pain diary. The patient will be contacted via telephone 72h after the intervention and asked about the pain level.~The intervention is finished after one consultation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy
Description: The treatment consists of an informing consultation, a planning CT scan and a series of 10 radiation sessions delivered over 3.5 weeks ( = 12 visits in total). The clinical target volume (CTV) will be defined based on the MRI and SPECT/CT. Planning target volume (PTV) will be expanded in all directions by 0.5 cm beyond the CTV. Patients will be treated in a supine position with minimum 6 MV photons and a 3D-technique or volumetric modulated arc therapy (VMAT)-technique. A kilovolt (kV) and in exception a cone-beam CT will be performed before each treatment for positioning accuracy. A dose of 0.5 Gy x 10 fractions (3 times per week) will be delivered over 3.5 weeks. Each radiotherapy treatment session takes approximately 15 minutes. If a second radiotherapy series will be done (NRS 4-10 at visit 4), the radiotherapy dose und fractionation will be the same as the first series.
Study: NCT05158218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic Exoskeleton Gait Therapy
Description: The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will be completed in a 60-minute sessions with rests as needed. The key components of the therapy will include: 1) optimally challenging activities of variable intensity that emphasize motor planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints, 2) task specific overground movements that promote building a repertoire of mobility strategies that can be utilized in the community, and 3) motor tasks requiring active control that increase participant therapeutic engagement. An overhead body weight support system or a gait-belt may be used for some individuals during the robotic exoskeleton gait training blocks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. An overhead body weight support system or a gait-belt may be used for some individuals during the gait training blocks
Study: NCT06563622

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Epidural Block
Description: USG-guided single-shot CEB in a dose of 0.5 mL/kg of 0.25% bupivacaine.
Study: NCT05956002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estraimod Immediate Release (IR)
Description: an immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estraimod Immediate Release (IR)
Description: an immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estraimod Immediate Release (IR)
Description: an immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estraimod Immediate Release (IR)
Description: an immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in water
Description: very small tablet mixed in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in water
Description: very small tablet mixed in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in water
Description: very small tablet mixed in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in water
Description: very small tablet mixed in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in chocolate pudding
Description: very small tablet mixed in chocolate pudding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in chocolate pudding
Description: very small tablet mixed in chocolate pudding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in chocolate pudding
Description: very small tablet mixed in chocolate pudding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in chocolate pudding
Description: very small tablet mixed in chocolate pudding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in yogurt
Description: Very small tablet mixed in yogurt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in yogurt
Description: Very small tablet mixed in yogurt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in yogurt
Description: Very small tablet mixed in yogurt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in yogurt
Description: Very small tablet mixed in yogurt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in applesauce
Description: Very small tablet mixed in applesauce

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in applesauce
Description: Very small tablet mixed in applesauce

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in applesauce
Description: Very small tablet mixed in applesauce

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in applesauce
Description: Very small tablet mixed in applesauce
Study: NCT05119010

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Continuous ketogenic diet
Description: ARM A : continuous ketogenic diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Discontinuous ketogenic diet
Description: ARM B : discontinuous ketogenic diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-hydroxybutyrate (BHB) supplementation
Description: ARM C : BHB supplementation
Study: NCT05010733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty using the Exeter V40 cemented femoral stem
Description: Consists of applying a cement layer of at least 2 millimeters surrounding an undersized prosthetic stem, so that this layer of cement fits between the femoral medullary canal and the prosthetic's femoral stem.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty using the Müller Straight Stem
Description: Consists of applying a thin layer of cement, so that the prosthetic's femoral stem fills as much as possible the femoral medullary canal.
Study: NCT05703035

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standby while firing staple
Description: VOLUNTEER PATIENTS WHO ACCEPT THE SURGERY WILL HAVE TISSUE CLOSURE AND CUTTING WITH STAPLER IN AVERAGE 30 MINUTES DURING THE SURGERY AND THE PATIENT WILL BE FOLLOWED FOR 30 DAYS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standby while firing staple
Description: VOLUNTEER PATIENTS WHO ACCEPT THE SURGERY WILL HAVE TISSUE CLOSURE AND CUTTING WITH STAPLER IN AVERAGE 30 MINUTES DURING THE SURGERY AND THE PATIENT WILL BE FOLLOWED FOR 30 DAYS.
Study: NCT05178771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: 1. Intravenous blood (obtained by venipuncture of the antecubital vein) will be collected in two 10-mL sterile tubes without any anticoagulants and will be immediately centrifuged at 3,000 revolutions (400 × g) per minute for 10 minutes.~2. A structured fibrin clot in the middle of the tube, just between the red corpuscles (RBCs) at the bottom and the acellular plasma at the top, will be separated from the RBCs using sterile tweezers and scissors and transferred on a sterile PRF box.~3. The PRF will be then brought to a thickness of 1 mm by gently compressing in PRF box. Standardized PRF pieces will be obtained by measuring by a periodontal probe and cutting into 3 × 5 mm dimensions.~4. The PRF pieces will be inserted into the periodontal pockets by filling the pockets from the base up to the gingival margin. A modified gingivectomy knife, of which the tip is made blunt, will be used.~The PRF volume will be calculated by recording how many pieces will be inserted.
Study: NCT04242329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical metastasectomy
Description: Surgical removal of metastases aimed at R0 resection.
Study: NCT05175209

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EMG
Description: Electromyelography
Study: NCT05206487

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: PDX will be started 2 weeks before TIPS and taken daily for a 6 month period after TIPS.
Study: NCT04242329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: Continued PD1-inhibitor treatment according to current treatment standards.
Study: NCT06255964

Intervention type: DRUG
Group type: OTHER
Intervention: IAP0971
Description: Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IAP0971＋BCG
Description: Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder perfusion,Maintain at months 3, 6, 12, 18, and 24Perfusion, once a week, three times in a row.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IAP0971＋BCG
Description: Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder irrigationNote, progress at months 3, 6, 12, 18, and 24Perform maintenance perfusion once a week, three times in a row.
Study: NCT05014893

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: multi-modal targeted intervention (e.g., cognitive training, exercise, games)
Description: The Intervention group will be given recommended interventions tailored to individuals based on their risks (e.g., physical exercise programs, cognitive training, dietary advice, control of blood pressure and cholesterol, healthy diet, control obesity, stop smoking,reduce alcohol excess)
Study: NCT05990036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sports vision enhancement training curriculum
Description: A curriculum of 8 sports vision training procedures applied during women's collegiate softball team training. The training protocol consists of once weekly training sessions, 45 minutes in duration.
Study: NCT05575635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib + concurrent radiotherapy + chemotherapy
Description: mFOLFOX6: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days, continuous infusion.~fruquintinib: 3mg/d, qd po, for 7 weeks continuously.~Radiation Therapy: radiation 45.0\~50.0 Gy (1.8-2.0 Gy/day or 25 fractions weeks 3-7)